

# Yaroslau Compta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/690370/publications.pdf>

Version: 2024-02-01

149  
papers

10,658  
citations

57631

44  
h-index

37111

96  
g-index

154  
all docs

154  
docs citations

154  
times ranked

11910  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-motor symptoms in spasmodic dysphonia: A case control-study. <i>Auris Nasus Larynx</i> , 2022, 49, 100-105.	0.5	1
2	Sex differences in brain atrophy and cognitive impairment in Parkinson's disease patients with and without probable rapid eye movement sleep behavior disorder. <i>Journal of Neurology</i> , 2022, 269, 1591-1599.	1.8	19
3	Assessment of Cognitive Symptoms in Brain Bank-Registered Control Subjects: Feasibility and Utility of a Telephone-Based Screening. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1107-1113.	1.2	0
4	Deep brain stimulation as a palliative treatment for myorhythmia: A case of failure. <i>European Journal of Neurology</i> , 2022, 29, 937-941.	1.7	2
5	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	5.8	34
6	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson's disease patients. <i>Npj Parkinson's Disease</i> , 2022, 8, 27.	2.5	8
7	Over-Mutated Mitochondrial, Lysosomal and TFEB-Regulated Genes in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 1749.	1.0	3
8	Smoking is associated with age at disease onset in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 79-83.	1.1	2
9	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
10	Brain atrophy pattern in de novo Parkinson's disease with probable RBD associated with cognitive impairment. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	9
11	Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 16-23.	1.1	32
12	Presentations and mechanisms of CNS disorders related to COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	52
13	Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. <i>Journal of Parkinson's Disease</i> , 2021, 11, 107-121.	1.5	28
14	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology</i> , The, 2021, 20, 107-116.	4.9	62
15	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	2.2	22
16	A comparative cost analysis between two quick diagnosis units of different levels of complexity. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 381-392.	0.6	2
17	Association of PSP phenotypes with survival: A brain-bank study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 77-81.	1.1	16
18	Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. <i>Journal of Parkinson's Disease</i> , 2021, 11, 685-694.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , 2021, 78, 464.	4.5	95
20	Enfermedad de Wilson: consideraciones para optimizar el seguimiento a largo plazo. <i>Gastroenterología Y Hepatología</i> , 2021, , .	0.2	0
21	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	2.8	29
22	Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 78-80.	1.1	7
23	Impaired Structural Connectivity in Parkinson's Disease Patients with Mild Cognitive Impairment: A Study Based on Probabilistic Tractography. <i>Brain Connectivity</i> , 2021, 11, 380-392.	0.8	10
24	Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 22-27.	1.1	26
25	Frequency and Characterization of Movement Disorders in Anti-IgLN5 Disease. <i>Neurology</i> , 2021, 97, .	1.5	50
26	Differentiation of multiple system atrophy subtypes by gray matter atrophy. <i>Journal of Neuroimaging</i> , 2021, , .	1.0	4
27	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	2.2	13
28	Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway. <i>Parkinsonism and Related Disorders</i> , 2021, , .	1.1	1
29	Cross-sectional associations of cerebrospinal $\alpha$ -synuclein, tau and amyloid- $\beta$ with dyskinesias, motor fluctuations, non-motor symptoms in a cohort of Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120033.	0.3	1
30	Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels. <i>Npj Parkinson's Disease</i> , 2021, 7, 109.	2.5	1
31	Disrupted functional connectivity in PD with probable RBD and its cognitive correlates. <i>Scientific Reports</i> , 2021, 11, 24351.	1.6	8
32	CCAAT/enhancer binding protein $\beta$ is a transcriptional repressor of $\alpha$ -synuclein. <i>Cell Death and Differentiation</i> , 2020, 27, 509-524.	5.0	14
33	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4-Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
34	Quick diagnosis units: predictors of time to diagnosis and costs. <i>Medicine (United States)</i> , 2020, 99, e21241.	0.4	1
35	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	1.1	8
36	<sc>MicroRNA</sc> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. <i>Movement Disorders</i> , 2020, 35, 1873-1879.	2.2	15

#	ARTICLE	IF	CITATIONS
37	Hemichorea as Presentation of Acute Cortical Ischemic Stroke. Case Series and Review of the Literature. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105150.	0.7	15
38	Peripheral insulin and amylin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 91-96.	1.1	20
39	Clinical Conditions "Suggestive of Progressive Supranuclear Palsy" Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	2.2	22
40	Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 951-958.	1.5	7
41	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	3.9	210
42	Copathology in Progressive Supranuclear Palsy: Does It Matter?. <i>Movement Disorders</i> , 2020, 35, 984-993.	2.2	48
43	Transcriptomic differences in MSA clinical variants. <i>Scientific Reports</i> , 2020, 10, 10310.	1.6	7
44	Increased CSF levels of IL-1 $\beta$ , IL-6, and ACE in SARS-CoV-2-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	69
45	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	2.2	31
46	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	2.2	57
47	Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 67-73.	1.1	23
48	Different Cortical Gyrfication Patterns in <i>Alzheimer's Disease</i> and Impact on Memory Performance. <i>Annals of Neurology</i> , 2020, 88, 67-80.	2.8	23
49	Primary progressive apraxia of speech: A further piece in the progressive supranuclear/corticobasal degeneration spectrum jigsaw. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 219-220.	1.1	2
50	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
51	Single-Center Complication Analysis Associated with Surgical Replacement of Implantable Pulse Generators in Deep Brain Stimulation. <i>Stereotactic and Functional Neurosurgery</i> , 2019, 97, 101-105.	0.8	4
52	A tear fluid proteome of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 1-2.	1.1	1
53	Setting in motion physiotherapy for MSAp. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 72-73.	1.1	1
54	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	4.9	1,414

#	ARTICLE	IF	CITATIONS
55	Differentiation of multiple system atrophy from Parkinson's disease by structural connectivity derived from probabilistic tractography. <i>Scientific Reports</i> , 2019, 9, 16488.	1.6	25
56	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	2.2	47
57	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66
58	Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 23, 101899.	1.4	11
59	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 3-12.	1.1	26
60	Malignant Glioma Developed on a Patient Under Deep Brain Stimulation: Pitfalls in Management. <i>World Neurosurgery</i> , 2019, 129, 85-89.	0.7	3
61	Progression of Parkinson's disease patients' subtypes based on cortical thinning: 4-year follow-up. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 286-292.	1.1	27
62	Cortical Gray Matter and Hippocampal Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2019, 10, 312.	1.1	31
63	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
64	Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1340-1350.	1.8	25
65	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
66	Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. <i>NeuroImage: Clinical</i> , 2019, 22, 101720.	1.4	34
67	Neurological profiles beyond the sleep disorder in patients with anti-IgLN5 disease. <i>Current Opinion in Neurology</i> , 2019, 32, 493-499.	1.8	43
68	Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 153-157.	1.1	59
69	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
70	SNCA but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. <i>Movement Disorders</i> , 2018, 33, 637-641.	2.2	25
71	Statistical inference in brain graphs using threshold-free network-based statistics. <i>Human Brain Mapping</i> , 2018, 39, 2289-2302.	1.9	53
72	Cortical atrophy patterns in early Parkinson's disease patients using hierarchical cluster analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 3-9.	1.1	57

#	ARTICLE	IF	CITATIONS
73	Ubiquinone, ubiquinol, 4-hydroxybenzoic acid   What is coenzyme Q10™ should we care about in multiple system atrophy?. Parkinsonism and Related Disorders, 2018, 50, 117-118.	1.1	1
74	Cerebrospinal fluid levels of alpha-synuclein in PARKINSON™S disease: Another long and winding road. Parkinsonism and Related Disorders, 2018, 49, 1-3.	1.1	4
75	Structural Brain Correlations of Visuospatial and Visuo-perceptual Tests in Parkinson™S Disease. Journal of the International Neuropsychological Society, 2018, 24, 33-44.	1.2	25
76	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
77	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 46, 16-23.	1.1	32
78	Cortical thinning correlates of changes in visuospatial and visuo-perceptual performance in Parkinson's disease: A 4-year follow-up. Parkinsonism and Related Disorders, 2018, 46, 62-68.	1.1	51
79	LRP10 in $\alpha$ -synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	4.9	11
80	Differential Progression of Regional Hippocampal Atrophy in Aging and Parkinson™S Disease. Frontiers in Aging Neuroscience, 2018, 10, 325.	1.7	26
81	Gray/White Matter Contrast in Parkinson™S Disease. Frontiers in Aging Neuroscience, 2018, 10, 89.	1.7	7
82	Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal $\beta$ , and $A\beta$ as well as dementia-risk in Parkinson's disease. Journal of the Neurological Sciences, 2017, 373, 223-229.	0.3	14
83	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
84	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
85	Brain correlates of progressive olfactory loss in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 41, 44-50.	1.1	32
86	CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.5	100
87	Discriminating cognitive status in Parkinson™S disease through functional connectomics and machine learning. Scientific Reports, 2017, 7, 45347.	1.6	88
88	Quick outpatient diagnosis in small district or general tertiary hospitals. Medicine (United States), 2017, 96, e6886.	0.4	6
89	What goes around comes around: cognitive impairment as prodromal parkinsonism?. Nature Reviews Neurology, 2017, 13, 709-710.	4.9	1
90	<sc>Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior. Brain and Behavior, 2017, 7, e00848.	1.0	17

#	ARTICLE	IF	CITATIONS
91	Conjoint FTLΔFUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy and Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 352-357.	1.8	2
92	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
93	Discovering the 3â² UTR-mediated regulation of alpha-synuclein. <i>Nucleic Acids Research</i> , 2017, 45, 12888-12903.	6.5	32
94	Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. <i>PLoS ONE</i> , 2017, 12, e0183843.	1.1	68
95	Lewyâ€and Alzheimerâ€™type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 451-462.	1.8	26
96	Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-Î² and Tau in Parkinsonâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1261-1272.	1.2	27
97	Nigral and striatal connectivity alterations in asymptomatic <i>LRRK2</i> mutation carriers: A magnetic resonance imaging study. <i>Movement Disorders</i> , 2016, 31, 1820-1828.	2.2	45
98	White matter hyperintensities, cerebrospinal amyloid-Î² and dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 367, 284-290.	0.3	26
99	Patterns of cortical thinning in nondemented Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 699-708.	2.2	71
100	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 668-675.	2.2	31
101	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78
102	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0132368.	1.1	67
103	Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinsonâ€™s Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	8
104	Restingâ€state frontostriatal functional connectivity in Parkinson's diseaseâ€™related apathy. <i>Movement Disorders</i> , 2015, 30, 671-679.	2.2	97
105	Correlates of cerebrospinal fluid levels of oligomeric- and total-Î±-synuclein in premotor, motor and dementia stages of Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
106	Cystatin <i>C</i> is differentially involved in multiple system atrophy phenotypes. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 507-519.	1.8	7
107	Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1170-1176.	1.1	43
108	The <i>ON</i> set of <i>NON</i> motor <i>S</i> ymptoms in <i>P</i> arkinson's disease ( <i>T</i> he <i>ONSET</i> <i>PD</i> <i>S</i> tudy). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402

#	ARTICLE	IF	CITATIONS
109	Cognitive impairment and resting-state network connectivity in Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 199-212.	1.9	264
110	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	1.4	178
111	Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1405-1410.	1.1	31
112	Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. <i>Movement Disorders</i> , 2014, 29, 1010-1018.	2.2	297
113	The Significance of $\alpha$ -Synuclein, Amyloid- $\beta$ and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. <i>Neurodegenerative Diseases</i> , 2014, 13, 154-156.	0.8	83
114	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology</i> , The, 2014, 13, 575-586.	4.9	436
115	Identification of blood serum microRNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2014, 92, 1071-1077.	1.3	122
116	Functional brain networks and cognitive deficits in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 4620-4634.	1.9	189
117	A novel non-rapid-eye movement (REM) and REM parasomnia with sleep breathing disorder associated with antibodies to IgLON5 and tau deposits at post-mortem study. <i>Journal of Neuroimmunology</i> , 2014, 275, 44-45.	1.1	3
118	Cortical thinning associated with mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1495-1503.	2.2	100
119	<sup>123</sup> I-MIBG cardiac uptake, smell identification and <sup>123</sup> I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 192-197.	1.1	30
120	Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease. <i>Journal of Neurology</i> , 2013, 260, 3002-3009.	1.8	15
121	Erratum to "Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study" [ <i>Parkinsonism &amp; Related Disorders</i> 19 (2013) 717-724]. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1071-1072.	1.1	4
122	The more cortical amyloid- $\beta$ , the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. <i>Movement Disorders</i> , 2013, 28, 263-264.	2.2	2
123	Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 717-724.	1.1	133
124	Cortical thinning is associated with disease stages and dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 875-882.	0.9	155
125	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. <i>Journal of Neurochemistry</i> , 2012, 123, 396-405.	2.1	64
126	Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 941-947.	1.1	53

#	ARTICLE	IF	CITATIONS
127	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 245-247.	1.1	34
128	Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. <i>Human Brain Mapping</i> , 2012, 33, 2521-2534.	1.9	184
129	Structural correlates of facial emotion recognition deficits in Parkinson's disease patients. <i>Neuropsychologia</i> , 2012, 50, 2121-2128.	0.7	110
130	High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal $\beta$ -amyloid in Parkinson disease. <i>Neuroscience Letters</i> , 2011, 487, 169-173.	1.0	18
131	Amyloid- $\beta$ and $\alpha$ , biomarkers in Parkinson's disease-dementia. <i>Journal of the Neurological Sciences</i> , 2011, 310, 25-30.	0.3	36
132	Identifying the genetic components underlying the pathophysiology of movement disorders. <i>The Application of Clinical Genetics</i> , 2011, 4, 81.	1.4	1
133	Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. <i>European Journal of Neurology</i> , 2011, 18, 980-987.	1.7	51
134	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. <i>Brain</i> , 2011, 134, 1493-1505.	3.7	497
135	Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. <i>Brain</i> , 2009, 132, 3308-3317.	3.7	133
136	Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2203-2210.	2.2	163
137	Diagnosis and the premotor phase of Parkinson disease. <i>Neurology</i> , 2009, 72, S12-20.	1.5	210
138	Fatal worsening of late-onset cerebellar ataxia with neuronal intranuclear inclusions due to superimposed meningeal Rosai-Dorfman disease. <i>Movement Disorders</i> , 2008, 23, 1488-1490.	2.2	2
139	Human central nervous system circuits examined through the electrodes implanted for deep brain stimulation. <i>Clinical Neurophysiology</i> , 2008, 119, 1219-1231.	0.7	18
140	Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. <i>Neuroscience Letters</i> , 2008, 448, 20-23.	1.0	54
141	Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 694-697.	1.4	36
142	Anticholinergic medications. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 121-125.	1.0	0
143	REM Sleep Behavior Disorder and Narcoleptic Features in Anti-Ma2-associated Encephalitis. <i>Sleep</i> , 2007, 30, 767-769.	0.6	115
144	Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. <i>Movement Disorders</i> , 2007, 22, 736-738.	2.2	8

#	ARTICLE	IF	CITATIONS
145	Long lasting pure freezing of gait preceding progressive supranuclear palsy: A clinicopathological study. <i>Movement Disorders</i> , 2007, 22, 1954-1958.	2.2	54
146	The silent period of the thenar muscles to contralateral and ipsilateral deep brain stimulation. <i>Clinical Neurophysiology</i> , 2006, 117, 2512-2520.	0.7	32
147	Excitability of subcortical motor circuits in Go/noGo and forced choice reaction time tasks. <i>Neuroscience Letters</i> , 2006, 406, 66-70.	1.0	45
148	Dystonia in Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, vii7-vii13.	1.8	116
149	Pure Autonomic Failure With Altered Dopamine Transporter Imaging. <i>Archives of Neurology</i> , 2006, 63, 604.	4.9	14